UNITED THERAPEUTICS Corp
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $105.59 | $110.08 | $104.52 | $107.79 | 20.60M |
| Jul 2, 2026 | $105.08 | $106.14 | $104.59 | $105.59 | 8.69M |
| Jul 1, 2026 | $105.32 | $106.13 | $104.68 | $105.08 | 17.82M |
| Jun 30, 2026 | $111.53 | $114.47 | $104.31 | $105.32 | 9.84M |
| Jun 29, 2026 | $109.56 | $113.23 | $107.69 | $111.53 | 8.72M |
| Jun 28, 2026 | $111.42 | $115.21 | $105.92 | $109.56 | 13.41M |
| Jun 27, 2026 | $110.54 | $113.17 | $109.79 | $111.42 | 19.09M |
| Jun 26, 2026 | $110.35 | $111.36 | $109.62 | $110.54 | 17.85M |
Company Overview
UNITED THERAPEUTICS Corp operates in the healthcare space within the Healthcare sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 13 · Independent 10 of 13| Date | Firm | Target | Rating |
|---|---|---|---|
| Jun 30 | JPMorgan | $168.34 | Reduce |
| Jun 21 | Mizuho | $102.76 | Strong Buy |
| Jun 3 | JPMorgan | $166.98 | Hold |
| May 13 | Truist Financial | $149.65 | Overweight |
| May 11 | Barclays | $116.14 | Neutral |
| May 6 | Rosenblatt | $182.02 | Overweight |
Politician Trades
View allWhat's Happening Right Now
- Sep 8, 2026 · Buyback ↗ — United Therapeutics announced a move to return $4B to shareholders via a new buyback program.
- Sep 8, 2026 · Buyback ↗ — The company launched a $477.6 million accelerated share repurchase agreement with Citi.
- Sep 17, 2026 · Insider ↗ — The CEO exercised 9,500 options and sold the matching shares under a preset 10b5-1 trading plan.
- Sep 18, 2026 · Insider ↗ — United Therapeutics' general counsel sold shares near the $500 price level.
- Sep 16, 2026 · Insider ↗ — Director Nilda Mesa sold 228 shares of United Therapeutics stock.
Snapshot
United Therapeutics generated $3.18B in revenue in FY2025, up 10.6% year-over-year, with net income of $1.33B representing a 41.9% margin. Operating income came in at $1.49B, while R&D spending totaled $550M, or 17% of revenue. The company produced $1.56B in operating cash flow and $1.04B in free cash flow after $520.5M of capital expenditures. United Therapeutics holds $1.56B in cash and equivalents against zero total debt, reflecting a fully unlevered balance sheet.
Bottom Line
United Therapeutics combines double-digit revenue growth, a 42% net margin, and a debt-free balance sheet with over $1.5B in cash, giving it substantial flexibility for reinvestment and shareholder returns, as evidenced by the new $4B buyback authorization and $477.6M accelerated share repurchase. Recurring, routine 10b5-1 insider sales by the CEO and other executives are notable in volume but appear programmatic rather than signaling a change in fundamentals. The core tradeoff is a highly profitable, cash-generative business with strong capital return commitments, set against a steady drumbeat of insider selling that investors should monitor for pattern changes.